1. Home
  2. FT vs CGEN Comparison

FT vs CGEN Comparison

Compare FT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.08

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.37

Market Cap

191.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
CGEN
Founded
1988
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
191.1M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
FT
CGEN
Price
$8.08
$2.37
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$5.00
AVG Volume (30 Days)
33.1K
272.6K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$75.09
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$1.30
52 Week High
$8.35
$3.24

Technical Indicators

Market Signals
Indicator
FT
CGEN
Relative Strength Index (RSI) 54.16 55.79
Support Level $8.00 $1.48
Resistance Level $8.32 $3.05
Average True Range (ATR) 0.07 0.10
MACD 0.00 0.04
Stochastic Oscillator 47.37 65.45

Price Performance

Historical Comparison
FT
CGEN

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: